Drug intelligence / Profile preview

APIRx-1701

Development stage: Preclinical
Lead developer: Incannex Healthcare
Modality: Small Molecules
Administration: Ophthalmic

Overview

APIRx-1701 is a preclinical ophthalmic cannabinoid-based drug candidate being developed for the treatment of glaucoma by APIRx Pharmaceuticals, now part of Incannex Healthcare. It is described in company and investor materials as a patented formulation within APIRx’s portfolio of medicinal cannabinoid drug products, targeting intraocular pressure–related pathology in glaucoma, with development currently at the in vitro, pre‑regulatory stage and no publicly disclosed specific molecular target or detailed mechanistic profile.[3][4][7][12]

Beyond the preview

Go deeper on APIRx-1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APIRx-1701.

Explore the full profile